Company
Cycle
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
3
3 still marketed
Novel approvals
0
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Cavhanza approved OrphanMay 29, 2026
- Harliku new use Priority reviewOrphanJun 10, 2025
- Tascenso Odt approved Dec 9, 2022
- Tascenso Odt approved Dec 23, 2021
- Harliku new use Sep 2, 2020
- Harliku approved OrphanJul 26, 2017
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (3)
Newest FDA action first.
- Cavhanza Nilotinib · 2026
- Tascenso Odt Fingolimod Lauryl Sulfate · 2022
- Harliku Nitisinone · 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.